
Gilead Sciences (GILD): HIV Strength Powers Growth, But Valuation Limits Upside
Gilead posted strong HIV-led growth, with base business sales up 16% and management raising full-year guidance. The stock still looks fairly valued near consensus, keeping the call at Hold.





